RxDoctor Payments Data

Neal Cabaluna, MD

Internal Medicine · Prescott, AZNPI 1871857359

Payments from drug & device makers

$1,753in general payments, 2019–2025

Across 90 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$414
  • Novo Nordisk$225
  • Pfizer$191
  • Lilly USA, LLC$159
  • Amgen$110
  • Sanofi-aventis U.S. LLC$89
  • plus $565 from 16 others

What the payments were for

  • Food & beverage$1,753100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,753 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$135,445
Medicare patients
334
Services billed
1,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol88$113,331
EliquisApixaban75$108,363
JardianceEmpagliflozin72$104,046
OzempicSemaglutide45$81,958
JanuviaSitagliptin Phosphate31$34,146
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$31,389
Soliqua 100-33Insulin Glargine/Lixisenatide26$30,637
MounjaroTirzepatide16$21,988
XareltoRivaroxaban13$20,444
Repatha SureclickEvolocumab14$20,074
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$17,763
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$16,340
Breo ElliptaFluticasone/Vilanterol16$15,902
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,830
VascepaIcosapent Ethyl11$11,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$414$131,093117 claims
PfizerEliquis$191$108,36375 claims
Novo NordiskOzempic$225$81,95845 claims
GSKTrelegy Ellipta, Breo Ellipta$78$47,29140 claims
MerckJanuvia, Belsomra$31$45,20442 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$89$32,01141 claims
Lilly USA, LLCMounjaro$159$21,98816 claims
Johnson & JohnsonXarelto$13$20,44413 claims
Idorsia Pharmaceuticals US IncQuviviq$17$5,83312 claims
AbbVieSynthroid$20$2,08334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →